Literature DB >> 2827887

Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.

J M Covey1, K W Kohn, D Kerrigan, E J Tilchen, Y Pommier.   

Abstract

4'-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA) is a DNA intercalating 9-aminoacridine with clinical activity in adult acute leukemia. m-AMSA has been shown to produce protein-linked DNA strand breaks in mammalian cells through an interaction with the nuclear enzyme DNA topoisomerase II. We have compared the effects of m-AMSA and several acridine analogues (9-aminoacridine; A, NSC 343499; B, SN 16507; C, NSC 140701; D, SN 13553) on DNA integrity and cell survival in L1210 leukemia in vitro. Cells (or isolated nuclei) were treated with drugs (0.1-50 microM) for 0.5-1.0 h and subsequently analyzed using the alkaline elution technique. All drugs, except Compound D, produced DNA-protein cross-links (DPC) in L1210 cells. At 1 microM, potency was in the order, C greater than m-AMSA greater than B greater than A much greater than 9-aminoacridine. In isolated nuclei, DPC and single-strand breaks were produced in essentially a 1:1 ratio, which is consistent with topoisomerase II-mediated protein-linked DNA breaks. Potency differences were less pronounced in nuclei than in cells. In isolated nuclei, Compound D produced extensive DPC not associated with single-strand breaks, which suggests a more complex activity for this compound. Colony formation assays demonstrated the cytotoxicity of most of these acridine analogues (C greater than B greater than A approximately equal to m-AMSA much greater than D = 9-aminoacridine). Correlation of DPC with cell kill gave similar curves for each compound. These results are evidence for a causal relationship between drug-induced topoisomerase II-mediated DNA breaks and cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.

Authors:  Ya Jin; Zimei Wu; Caibin Li; Weisai Zhou; John P Shaw; Bruce C Baguley; Jianping Liu; Wenli Zhang
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

3.  Development of a novel assay for human tyrosyl DNA phosphodiesterase 2.

Authors:  Sanjay Adhikari; Soumendra K Karmahapatra; Hadi Elias; Priyanka Dhopeshwarkar; R Scott Williams; Stephen Byers; Aykut Uren; Rabindra Roy
Journal:  Anal Biochem       Date:  2011-05-12       Impact factor: 3.365

Review 4.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

5.  Activity and mode of action of acridine compounds against Leishmania donovani.

Authors:  C M Mesa-Valle; J Castilla-Calvente; M Sanchez-Moreno; V Moraleda-Lindez; J Barbe; A Osuna
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro.

Authors:  K A Werbovetz; E K Lehnert; T L Macdonald; R D Pearson
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

7.  Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.

Authors:  S Withoff; E G de Vries; W N Keith; E F Nienhuis; W T van der Graaf; D R Uges; N H Mulder
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

8.  Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.

Authors:  Wenli Zhang; Caibin Li; Ya Jin; Xinyue Liu; Zhiyu Wang; John P Shaw; Bruce C Baguley; Zimei Wu; Jianping Liu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

9.  Hyperthermia, thermotolerance and topoisomerase II inhibitors.

Authors:  H H Kampinga
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

10.  Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.

Authors:  Hannah C Wise; Gopakumar V Iyer; Kathleen Moore; Sarah M Temkin; Sarah Gordon; Carol Aghajanian; Rachel N Grisham
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.